Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study.

Li, Shenglong; Zheng, Hao; Ge, Qinghong; Xia, Shuli; Zhang, Ke; Wang, Chunjing; Wang, Fujing

Li, Shenglong; Zheng, Hao; Ge, Qinghong; Xia, Shuli; Zhang, Ke; Wang, Chunjing; Wang, Fujing.

Afiliación

Li S; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zheng H; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Ge Q; Department of Internal Medicine, Harbin Orthopedics Hospital, Harbin, China.
Xia S; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhang K; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wang C; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wang F; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

J Cancer Prev ; 28(3): 106-114, 2023 Sep 30.

Article en En | MEDLINE | ID: mdl-37830117

Palabras clave

Apatinib; Efficacy; Metastatic colorectal cancer; Programmed cell death protein 1 blockades; Safety

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Cancer Prev Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google